| [1] |
陈万青，郑荣寿. 中国女性乳腺癌发病死亡和生存状况[J]. 中国肿瘤临床，2015，42(13)：668-674.
|
| [2] |
孙强. 对乳腺癌新辅助化疗指征的探讨[J/CD]. 中华乳腺病杂志(电子版), 2015，9(5)：287-291.
|
| [3] |
Viale G. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy[J]. Breast, 2013, 22 Suppl 2(3): S88.
|
| [4] |
Simos D, Clemons M, Ginsburg OM, et al. Definition and consequences of locally advanced breast cancer[J]. Curr Opin Support Palliat Care, 2014, 8(1): 33-38.
|
| [5] |
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007, 25(28): 4414-4422.
|
| [6] |
MD Anderson Cancer Center. Residual cancer burden calculator[CP/OL]. Texas: MD Anderson Cancer Center.[20117-01-08]．
URL
|
| [7] |
Peintinger F, Sinn B, Hatzis C, et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy[J]. Mod Pathol, 2015, 28(7): 913-920.
|
| [8] |
Romero A, García-Sáenz JA, Fuentes-Ferrer M, et al. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients[J]．Ann Oncol, 2013, 24(3): 655-661.
|
| [9] |
Nahleh Z, Sivasubramaniam D, Dhaliwal S, et al. Residual cancer burden in locally advanced breast cancer: a superior tool[J]. Curr Oncol, 2008, 15(6): 271-278.
|
| [10] |
Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J]. J Clin Oncol, 2017, 35(10): 1049-1060.
|
| [11] |
梁璟慧，吴毓东，杨丽萍. 三阴性乳腺癌新辅助化疗的最新进展[J/CD]. 中华乳腺病杂志(电子版), 2015, 9(4)：270-274.
|
| [12] |
Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study[J]. Lancet Oncol, 2012, 13(4): 375-84.
|
| [13] |
Sharma P, Lópeztarruella S, Garcíasaenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts[J]. Clin Cancer Res, 2017, 23(3): 649-657.
|
| [14] |
Peintinger F, Buzdar AU, Kuerer HM, et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab[J]. Ann Oncol, 2008, 19(12): 2020-2025.
|
| [15] |
Naidoo K, Parham DM, Pinder SE. An audit of residual cancer burden reproducibility in a UK context[J]. Histopathology, 2017, 70(2), 217-222.
|
| [16] |
Pasam R, Sivarama TV, Nagakishore MG. Cytomorphological changes in breast carcinomas, after neoadjuvant chemotherapy: a study of twenty cases[J]. Int J Res Med Sci, 2015, 3(11): 3326-3330.
|
| [17] |
Bossuyt MD, Symmans WF. Standardizing of pathology in patients receiving neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2016, 23(10): 3153-3161.
|
| [18] |
Braeuning MP, Burke ET, Pisano ED. Embolization coils as tumor markers for mammography in patients undergoing neoadjuvant chemotherapy for carcinoma of the breast[J]. AJR Am J Roentgenol, 2000, 174(1): 251-252.
|
| [19] |
Houssami N, Ciatto S, Turner RM, et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla[J]. Ann Surg, 2011, 254(2): 243-251.
|
| [20] |
Tudorica A, Oh KY, Chui SY, et al. Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI[J]. Transl Oncol, 2016, 9(1): 8-17.
|
| [21] |
Lim EA, Gunther JE, Kim HK, et al. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients[J]. Breast Cancer Res Treat, 2017, 162(3): 533-540.
|
| [22] |
Lee SM, Bae SK, Kim TH, et al. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy[J]. Clin Nucl Med, 2014, 39(10): 882-886.
|
| [23] |
Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2009, 116(1): 53-68.
|
| [24] |
Sheri A, Smith IE, Johnston SR, et al. Residual Proliferative Cancer Burden to predict long-term outcome following neoadjuvant chemotherapy[J]. Ann Oncol, 2015, 26(1): 75-80.
|
| [25] |
Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29(32): 4273-4278.
|
| [26] |
Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences[J]. Apoptosis, 2006, 11(10): 1709-1726.
|
| [27] |
Exner R, Sachet M, Arnold T, et al. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy[J]. Cancer Med, 2016, 5(9): 2350-2358.
|